TNF and neoplasm: To corroborate our in vitro characterisation studies in preclinical disease models, we constructed transmorphic particles bearing a transgene encoding TNFα, a known anti‐tumour cytokine, for the treatment of NOD/SCID immunodeficient mice bearing subcutaneous GBM001 tumours.